Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€254.90

€254.90

0.490%
1.25
0.490%
€308.19
 
21.08.25 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Amgen Inc. Stock

The Amgen Inc. stock is trending slightly upwards today, with an increase of €1.25 (0.490%) compared to yesterday's price.
With 24 Buy predictions and 4 Sell predictions Amgen Inc. is one of the favorites of our community.
As a result the target price of 308 € shows a positive potential of 20.83% compared to the current price of 254.9 € for Amgen Inc..
Criterium "Balance Sheet Risk" is seen as the biggest plus for Amgen Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Amgen Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Amgen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amgen Inc. 0.490% 2.287% 0.711% -13.666% 1.736% 2.021% 26.470%
Regeneron Pharmaceuticals Inc. 2.050% 6.156% 10.525% -51.473% -23.773% -16.299% 0.448%
Exact Sciences 0.560% 4.439% -2.513% -24.594% -25.800% 10.020% -40.670%
Incyte Corp. 0.780% 0.838% 29.424% 29.649% 13.512% 0.498% -6.505%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.

Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.

Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.

Comments

Prediction Sell
Perf. (%) -2.62%
Target price 222.320
Change
Ends at 23.07.26

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Corporation from $252.00 to $261.00. They now have an "underperform" rating on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 7.01%
Target price 280.342
Change
Ends at 27.06.26

Amgen Inc. (NASDAQ: AMGN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $328.00 price target on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for AMGN provided by MarketBeat
Show more

News

Amgen (AMGN) Q2 Profit Jumps 21%
Amgen (AMGN) Q2 Profit Jumps 21%

Amgen (NASDAQ:AMGN), a leading biotechnology company with a wide portfolio of innovative medicines, released its second-quarter 2025 results on August 5, 2025. The headline news was a double-digit

2 Dividend Stocks You Won't Find in the Schwab U.S. Dividend Equity ETF (SCHD). And They're Better Buys.: https://g.foolcdn.com/editorial/images/826984/copy-of-dividends-blackboard-sketch-doodle-1201x849-0ca0aea.jpg
2 Dividend Stocks You Won't Find in the Schwab U.S. Dividend Equity ETF (SCHD). And They're Better Buys.

If you're looking to invest in dividend stocks, one of the most popular ways to do it is with the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD). The exchange-traded fund (ETF) has net assets of

2 Top Dividend Stocks to Buy Right Now and Hold Forever: https://g.foolcdn.com/editorial/images/826036/pharmacist-talking-to-patient.jpg
2 Top Dividend Stocks to Buy Right Now and Hold Forever

Over the long run, dividends can make a significant difference in your returns, whether you choose to reinvest the payouts or retain the cash for other purposes. However, many companies that offer